Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Relief Therapeutics Holding AG    RLF   CH0100191136

RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Relief Therapeutics : Announces Capital Increase from its Final Tranche of the Share Subscription Facility with GEM

share with twitter share with LinkedIn share with facebook
09/28/2020 | 02:05am EDT

EQS Group-News: Relief Therapeutics Holdings AG / Key word(s): Capital Increase
Relief Announces Capital Increase from its Final Tranche of the Share Subscription Facility with GEM

28.09.2020 / 07:00


Relief Announces Capital Increase from its Final Tranche of the Share Subscription Facility with GEM

Geneva, Switzerland, September 28, 2020 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100 (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced a capital increase pursuant to a drawdown of its Share Subscription Facility (SSF) with the Company's main shareholder GEM Global Yield Fund LLC SCS ("GEM").

Funds raised amount to CHF 17,949,600. The available cash on the balance sheet of the Company, after receipt of the funds, will be approximately CHF 48,000,000 and will be used primarily to fund the ongoing Fast Track FDA trial of RLF-100 (IV) in COVID-19 acute respiratory distress syndrome (NCT04311697) and the RLF-100 (inhaled) trial for the treatment of non-acute lung injury in COVID-19 (NCT04360096) as well as to run a phase 3 study in Europe. Relief believes that with the conclusion of this raise, its capital resources will be sufficient to support its planned operations through 2022, without taking into account potential revenues generated from sales of RLF-100. Execution of the SSF, together with the latest exercises of stock options, will bring the total amount of shares outstanding to 2,580,068,581.

Relief and GEM have agreed on an amendment to the SSF to increase the remaining balance by CHF 6,000,000 before the conclusion of this tranche. This action concludes the existing SSF and Relief has no plans to put a new one in place.

"We are now well funded to progress all ongoing and planned RLF-100 trials for COVID-19 indications and are on course to reach our next milestones. In the midst of the largest health crisis of our time, we remain committed to doing our part to ensure that as many patients as possible can quickly benefit from this potentially life-saving therapeutic option," said Raghuram (Ram) Selvaraju, Chairman of the Board of Relief.

About Relief
Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100 (aviptadil), synthetic vasoactive intestinal peptide (VIP), is being investigated in two placebo-controlled US Phase IIb/III clinical trials in respiratory deficiency due to COVID-19. RLF-100 is believed to be the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. Since July 2020, severe COVID-19 patients have been treated with RLF-100 under U.S. FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment of respiratory failure in COVID-19.

Relief holds orphan drug designations from the U.S. FDA and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF.

CONTACT
RELIEF THERAPEUTICS Holding SA

Raghuram (Ram) Selvaraju, Ph.D., MBA
Chairman of the Board
Mail: contact@relieftherapeutics.com

FOR MEDIA INQUIRES:
MC Services AG

Anne Hennecke / Brittney Sojeva
Mail: relief@mc-services.eu
Tel.: +49 (0) 211-529-252-14

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.



End of Media Release


Language: English
Company: Relief Therapeutics Holdings AG
Avenue de Sécheron 15
1202 Genève
Switzerland
E-mail: contact@relieftherapeutics.com
Internet: https://relieftherapeutics.com
ISIN: CH0100191136
Listed: SIX Swiss Exchange
EQS News ID: 1136765

 
End of News EQS Group News Service

1136765  28.09.2020 

fncls.ssp?fn=show_t_gif&application_id=1136765&application_name=news&site_id=zonebourse
© EQS 2020

share with twitter share with LinkedIn share with facebook
All news about RELIEF THERAPEUTICS HOLDING AG
10/23RELIEF THERAPEUTICS : NeuroRx and Relief announce topline efficacy data from pat..
PU
10/13RELIEF THERAPEUTICS : says some COVID-19 patients who got its drug survived long..
RE
10/13RELIEF THERAPEUTICS : NeuroRx and Relief announce topline efficacy data from pat..
EQ
10/13NEURORX : and Relief announce topline efficacy data from patients treated with R..
PR
10/08RELIEF THERAPEUTICS : Appoints Industry Veteran, Jack Weinstein, as Chief Financ..
EQ
09/30RELIEF THERAPEUTICS : NeuroRx and Relief Therapeutics Establish Supply and Distr..
EQ
09/28RELIEF THERAPEUTICS : Announces Capital Increase from its Final Tranche of the S..
PU
09/28RELIEF THERAPEUTICS : deal with biggest owner lifts cash to $52 mln for COVID-19..
RE
09/28RELIEF THERAPEUTICS : deal with biggest owner lifts cash to $52 mln for COVID-19..
RE
09/28RELIEF THERAPEUTICS : Announces Capital Increase from its Final Tranche of the S..
EQ
More news
Financials
Sales 2019 - - -
Net income 2019 -7,46 M -8,13 M -8,13 M
Net Debt 2019 1,61 M 1,76 M 1,76 M
P/E ratio 2019 -0,28x
Yield 2019 -
Capitalization 1 266 M 1 382 M 1 381 M
EV / Sales 2018 20,5x
EV / Sales 2019 -
Nbr of Employees 10
Free-Float 64,7%
Chart RELIEF THERAPEUTICS HOLDING AG
Duration : Period :
Relief Therapeutics Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RELIEF THERAPEUTICS HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Managers
NameTitle
Raghuram Selvaraju Chairman
Jack M. Weinstein Chief Financial Officer & Treasurer
Gilles Della Corte Chief Medical Officer
Peter Egon de Svastich Director
Jonathan C. Javitt Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
RELIEF THERAPEUTICS HOLDING AG48,600.00%1 382
LONZA GROUP AG57.19%45 022
IQVIA HOLDINGS INC.-0.34%29 650
SEAGEN INC.45.98%29 023
CELLTRION, INC.33.15%28 374
MODERNA, INC.244.94%26 623